ID   PTN6_HUMAN              Reviewed;         595 AA.
AC   P29350; A8K306; G3V0F8; Q969V8; Q9UK67;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   10-MAY-2017, entry version 204.
DE   RecName: Full=Tyrosine-protein phosphatase non-receptor type 6;
DE            EC=3.1.3.48;
DE   AltName: Full=Hematopoietic cell protein-tyrosine phosphatase;
DE   AltName: Full=Protein-tyrosine phosphatase 1C;
DE            Short=PTP-1C;
DE   AltName: Full=Protein-tyrosine phosphatase SHP-1;
DE   AltName: Full=SH-PTP1;
GN   Name=PTPN6; Synonyms=HCP, PTP1C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1732748; DOI=10.1128/MCB.12.2.836;
RA   Yi T., Cleveland J.L., Ihle J.N.;
RT   "Protein tyrosine phosphatase containing SH2 domains:
RT   characterization, preferential expression in hematopoietic cells, and
RT   localization to human chromosome 12p12-p13.";
RL   Mol. Cell. Biol. 12:836-846(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Mammary gland;
RX   PubMed=1652101; DOI=10.1038/352736a0;
RA   Shen S.H., Bastien L., Posner B.I., Chretien P.;
RT   "A protein-tyrosine phosphatase with sequence similarity to the SH2
RT   domain of the protein-tyrosine kinases.";
RL   Nature 352:736-739(1991).
RN   [3]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Shen S.H., Bastien L., Posner B.I., Chretien P.;
RL   Nature 353:868-868(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1736296; DOI=10.1073/pnas.89.3.1123;
RA   Plutzky J., Neel B.G., Rosenberg R.D.;
RT   "Isolation of a src homology 2-containing tyrosine phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:1123-1127(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2 AND 3).
RX   PubMed=7665165; DOI=10.1006/geno.1995.1020;
RA   Banville D., Stocco R., Shen S.H.;
RT   "Human protein tyrosine phosphatase 1C (PTPN6) gene structure:
RT   alternate promoter usage and exon skipping generate multiple
RT   transcripts.";
RL   Genomics 27:165-173(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9074930; DOI=10.1101/gr.7.3.268;
RA   Ansari-Lari M.A., Shen Y., Muzny D.M., Lee W., Gibbs R.A.;
RT   "Large-scale sequencing in human chromosome 12p13: experimental and
RT   computational gene structure determination.";
RL   Genome Res. 7:268-280(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RX   PubMed=10497187; DOI=10.1074/jbc.274.40.28301;
RA   Jin Y.J., Yu C.L., Burakoff S.J.;
RT   "Human 70-kDa SHP-1L differs from 68-kDa SHP-1 in its C-terminal
RT   structure and catalytic activity.";
RL   J. Biol. Chem. 274:28301-28307(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2).
RA   Oka T., Ouchida M.;
RT   "Gene silencing of SHP-1 gene in leukemias/lymphomas by aberrant
RT   methylation.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PHOSPHORYLATION.
RX   PubMed=7781604;
RA   Li R.Y., Gaits F., Ragab A., Ragab-Thomas J.M.F., Chap H.;
RT   "Tyrosine phosphorylation of an SH2-containing protein tyrosine
RT   phosphatase is coupled to platelet thrombin receptor via a pertussis
RT   toxin-sensitive heterotrimeric G-protein.";
RL   EMBO J. 14:2519-2526(1995).
RN   [14]
RP   INTERACTION WITH LILRB1.
RX   PubMed=9285411; DOI=10.1016/S1074-7613(00)80529-4;
RA   Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L.,
RA   Hsu M.-L.;
RT   "A novel immunoglobulin superfamily receptor for cellular and viral
RT   MHC class I molecules.";
RL   Immunity 7:273-282(1997).
RN   [15]
RP   INTERACTION WITH LILRB2.
RX   PubMed=9842885;
RX   DOI=10.1002/(SICI)1521-4141(199811)28:11<3423::AID-IMMU3423>3.0.CO;2-2;
RA   Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R.,
RA   Borges L.;
RT   "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-
RT   mediated signaling in monocytes.";
RL   Eur. J. Immunol. 28:3423-3434(1998).
RN   [16]
RP   INTERACTION WITH PTPNS1.
RX   PubMed=9712903; DOI=10.1074/jbc.273.35.22719;
RA   Veillette A., Thibaudeau E., Latour S.;
RT   "High expression of inhibitory receptor SHPS-1 and its association
RT   with protein tyrosine phosphatase SHP-1 in macrophages.";
RL   J. Biol. Chem. 273:22719-22728(1998).
RN   [17]
RP   INTERACTION WITH LYN, AND PHOSPHORYLATION AT TYR-564.
RX   PubMed=10574931; DOI=10.1074/jbc.274.49.34663;
RA   Yoshida K., Kharbanda S., Kufe D.;
RT   "Functional interaction between SHPTP1 and the Lyn tyrosine kinase in
RT   the apoptotic response to DNA damage.";
RL   J. Biol. Chem. 274:34663-34668(1999).
RN   [18]
RP   INTERACTION WITH FCRL2 AND FCRL3.
RX   PubMed=11162587; DOI=10.1006/bbrc.2000.4213;
RA   Xu M.-J., Zhao R., Zhao Z.J.;
RT   "Molecular cloning and characterization of SPAP1, an inhibitory
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 280:768-775(2001).
RN   [19]
RP   INTERACTION WITH CD84.
RX   PubMed=11414741; DOI=10.1006/clim.2001.5035;
RA   Lewis J., Eiben L.J., Nelson D.L., Cohen J.I., Nichols K.E.,
RA   Ochs H.D., Notarangelo L.D., Duckett C.S.;
RT   "Distinct interactions of the X-linked lymphoproliferative syndrome
RT   gene product SAP with cytoplasmic domains of members of the CD2
RT   receptor family.";
RL   Clin. Immunol. 100:15-23(2001).
RN   [20]
RP   FUNCTION IN ROS1 DEPHOSPHORYLATION, AND INTERACTION WITH ROS1.
RX   PubMed=11266449; DOI=10.1083/jcb.152.2.325;
RA   Keilhack H., Mueller M., Boehmer S.A., Frank C., Weidner K.M.,
RA   Birchmeier W., Ligensa T., Berndt A., Kosmehl H., Guenther B.,
RA   Mueller T., Birchmeier C., Boehmer F.D.;
RT   "Negative regulation of Ros receptor tyrosine kinase signaling. An
RT   epithelial function of the SH2 domain protein tyrosine phosphatase
RT   SHP-1.";
RL   J. Cell Biol. 152:325-334(2001).
RN   [21]
RP   INTERACTION WITH FCRL4.
RX   PubMed=14597715; DOI=10.1073/pnas.1935944100;
RA   Ehrhardt G.R.A., Davis R.S., Hsu J.T., Leu C.-M., Ehrhardt A.,
RA   Cooper M.D.;
RT   "The inhibitory potential of Fc receptor homolog 4 on memory B
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:13489-13494(2003).
RN   [22]
RP   INTERACTION WITH CD300LF.
RX   PubMed=15184070; DOI=10.1016/j.bbrc.2004.05.065;
RA   Sui L., Li N., Liu Q., Zhang W., Wan T., Wang B., Luo K., Sun H.,
RA   Cao X.;
RT   "IgSF13, a novel human inhibitory receptor of the immunoglobulin
RT   superfamily, is preferentially expressed in dendritic cells and
RT   monocytes.";
RL   Biochem. Biophys. Res. Commun. 319:920-928(2004).
RN   [23]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [24]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [25]
RP   INTERACTION WITH KIR2DL1.
RX   PubMed=18604210; DOI=10.1038/ni.1635;
RA   Yu M.-C., Su L.-L., Zou L., Liu Y., Wu N., Kong L., Zhuang Z.-H.,
RA   Sun L., Liu H.P., Hu J.-H., Li D., Strominger J.L., Zang J.-W.,
RA   Pei G., Ge B.-X.;
RT   "An essential function for beta-arrestin 2 in the inhibitory signaling
RT   of natural killer cells.";
RL   Nat. Immunol. 9:898-907(2008).
RN   [26]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PDPK1.
RX   PubMed=19591923; DOI=10.1016/j.cellsig.2009.06.010;
RA   Sephton C.F., Zhang D., Lehmann T.M., Pennington P.R., Scheid M.P.,
RA   Mousseau D.D.;
RT   "The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is
RT   dependent on its association with the protein tyrosine phosphatase
RT   SHP-1.";
RL   Cell. Signal. 21:1634-1644(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-64, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CDK2.
RX   PubMed=21262353; DOI=10.1016/j.cellsig.2011.01.019;
RA   Fiset A., Xu E., Bergeron S., Marette A., Pelletier G.,
RA   Siminovitch K.A., Olivier M., Beauchemin N., Faure R.L.;
RT   "Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and
RT   regulates insulin internalization.";
RL   Cell. Signal. 23:911-919(2011).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 248-399.
RX   PubMed=9774441; DOI=10.1074/jbc.273.43.28199;
RA   Yang J., Liang X., Niu T., Meng W., Zhao Z., Zhou G.W.;
RT   "Crystal structure of the catalytic domain of protein-tyrosine
RT   phosphatase SHP-1.";
RL   J. Biol. Chem. 273:28199-28207(1998).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-532, AND DOMAIN SH2.
RX   PubMed=12482860; DOI=10.1074/jbc.M210430200;
RA   Yang J., Liu L., He D., Song X., Liang X., Zhao Z.J., Zhou G.W.;
RT   "Crystal structure of human protein-tyrosine phosphatase SHP-1.";
RL   J. Biol. Chem. 278:6516-6520(2003).
RN   [34]
RP   STRUCTURE BY NMR OF 110-214.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structures of the SH2 domain of human protein-tyrosine
RT   phosphatase SHP-1.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS), AND DOMAIN SH2.
RX   PubMed=21465528; DOI=10.1002/jcb.23125;
RA   Wang W., Liu L., Song X., Mo Y., Komma C., Bellamy H.D., Zhao Z.J.,
RA   Zhou G.W.;
RT   "Crystal structure of human protein tyrosine phosphatase SHP-1 in the
RT   open conformation.";
RL   J. Cell. Biochem. 112:2062-2071(2011).
CC   -!- FUNCTION: Modulates signaling by tyrosine phosphorylated cell
CC       surface receptors such as KIT and the EGF receptor/EGFR. The SH2
CC       regions may interact with other cellular components to modulate
CC       its own phosphatase activity against interacting substrates.
CC       Together with MTUS1, induces UBE2V2 expression upon angiotensin II
CC       stimulation. Plays a key role in hematopoiesis.
CC       {ECO:0000269|PubMed:11266449}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044}.
CC   -!- SUBUNIT: Monomer. Interacts with MTUS1 (By similarity). Interacts
CC       with MILR1 (tyrosine-phosphorylated). Interacts with KIT (By
CC       similarity). Binds PTPNS1, LILRB1 and LILRB2. Interacts with
CC       FCRL2, FCRL3, FCRL4, CD300LF, CDK2 and CD84. Interacts with
CC       KIR2DL1; the interaction is enhanced by ARRB2. Interacts (via SH2
CC       1 domain) with ROS1; the interaction is direct and promotes ROS1
CC       dephosphorylation. Interacts with EGFR; inhibits EGFR-dependent
CC       activation of MAPK/ERK. Interacts with LYN. Interacts with the
CC       tyrosine phosphorylated form of PDPK1. Interacts with CEACAM1 (via
CC       cytoplasmic domain); this interaction depends on the monomer/dimer
CC       equilibrium and is phosphorylation-dependent (By similarity).
CC       {ECO:0000250, ECO:0000250|UniProtKB:P29351,
CC       ECO:0000269|PubMed:10574931, ECO:0000269|PubMed:11162587,
CC       ECO:0000269|PubMed:11266449, ECO:0000269|PubMed:11414741,
CC       ECO:0000269|PubMed:14597715, ECO:0000269|PubMed:15184070,
CC       ECO:0000269|PubMed:18604210, ECO:0000269|PubMed:19591923,
CC       ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:9285411,
CC       ECO:0000269|PubMed:9712903, ECO:0000269|PubMed:9842885}.
CC   -!- INTERACTION:
CC       Q14790:CASP8; NbExp=3; IntAct=EBI-78260, EBI-78060;
CC       P20273:CD22; NbExp=4; IntAct=EBI-78260, EBI-78277;
CC       P20138:CD33; NbExp=8; IntAct=EBI-78260, EBI-3906571;
CC       P11049:CD37; NbExp=4; IntAct=EBI-78260, EBI-6139068;
CC       P19235:EPOR; NbExp=11; IntAct=EBI-78260, EBI-617321;
CC       P31994:FCGR2B; NbExp=3; IntAct=EBI-78260, EBI-724784;
CC       Q13643:FHL3; NbExp=3; IntAct=EBI-78260, EBI-741101;
CC       P62993:GRB2; NbExp=3; IntAct=EBI-78260, EBI-401755;
CC       P43626:KIR2DL1; NbExp=4; IntAct=EBI-78260, EBI-8684277;
CC       P43628:KIR2DL3; NbExp=13; IntAct=EBI-78260, EBI-8632435;
CC       Q6GTX8:LAIR1; NbExp=5; IntAct=EBI-78260, EBI-965864;
CC       P06239:LCK; NbExp=5; IntAct=EBI-78260, EBI-1348;
CC       P16284:PECAM1; NbExp=4; IntAct=EBI-78260, EBI-716404;
CC       Q9UKJ1:PILRA; NbExp=5; IntAct=EBI-78260, EBI-965833;
CC       Q05397:PTK2; NbExp=3; IntAct=EBI-7399369, EBI-702142;
CC       P08922:ROS1; NbExp=2; IntAct=EBI-78260, EBI-7371065;
CC       Q8N1K5:THEMIS; NbExp=4; IntAct=EBI-78260, EBI-2873538;
CC       B7UM99:tir (xeno); NbExp=4; IntAct=EBI-78260, EBI-2504426;
CC       Q7DB77:tir (xeno); NbExp=2; IntAct=EBI-78260, EBI-6480811;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=In neurons,
CC       translocates into the nucleus after treatment with angiotensin II
CC       (By similarity). Shuttles between the cytoplasm and nucleus via
CC       its association with PDPK1. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long;
CC         IsoId=P29350-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29350-3; Sequence=VSP_007775;
CC       Name=3; Synonyms=Short;
CC         IsoId=P29350-2; Sequence=VSP_005129, VSP_005130;
CC       Name=4; Synonyms=70-kDa, SHP-1L;
CC         IsoId=P29350-4; Sequence=VSP_044447;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in hematopoietic cells.
CC       Isoform 2 is expressed in non-hematopoietic cells.
CC   -!- DOMAIN: The N-terminal SH2 domain functions as an auto-inhibitory
CC       domain, blocking the catalytic domain in the ligand-free close
CC       conformation. {ECO:0000269|PubMed:12482860,
CC       ECO:0000269|PubMed:21465528}.
CC   -!- PTM: Phosphorylated on tyrosine residues. Binding of KITLG/SCF to
CC       KIT increases tyrosine phosphorylation (By similarity).
CC       Phosphorylation at Tyr-564 enhances phosphatase activity.
CC       {ECO:0000250, ECO:0000269|PubMed:10574931,
CC       ECO:0000269|PubMed:7781604}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Non-receptor class 2 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTPN6ID41920ch12p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M74903; AAA35963.1; -; mRNA.
DR   EMBL; X62055; CAA43982.1; -; mRNA.
DR   EMBL; M77273; AAA36610.1; -; mRNA.
DR   EMBL; U15528; AAA82880.1; -; Genomic_DNA.
DR   EMBL; U15536; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15535; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15534; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15533; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15532; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15531; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15530; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15529; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15528; AAA82879.1; -; Genomic_DNA.
DR   EMBL; U15537; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15535; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15534; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15533; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15532; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15531; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15530; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15529; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U47924; AAB51322.1; -; Genomic_DNA.
DR   EMBL; U47924; AAB51323.1; -; Genomic_DNA.
DR   EMBL; AF178946; AAD53317.1; -; mRNA.
DR   EMBL; AB079851; BAC81774.1; -; Genomic_DNA.
DR   EMBL; AB079851; BAC81775.1; -; Genomic_DNA.
DR   EMBL; AK290421; BAF83110.1; -; mRNA.
DR   EMBL; CH471116; EAW88703.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88704.1; -; Genomic_DNA.
DR   EMBL; BC002523; AAH02523.1; -; mRNA.
DR   EMBL; BC007667; AAH07667.1; -; mRNA.
DR   CCDS; CCDS41744.1; -. [P29350-3]
DR   CCDS; CCDS44820.1; -. [P29350-1]
DR   CCDS; CCDS44821.1; -. [P29350-4]
DR   PIR; B42031; S20825.
DR   RefSeq; NP_002822.2; NM_002831.5. [P29350-1]
DR   RefSeq; NP_536858.1; NM_080548.4. [P29350-3]
DR   RefSeq; NP_536859.1; NM_080549.3. [P29350-4]
DR   RefSeq; XP_011519290.1; XM_011520988.1. [P29350-3]
DR   UniGene; Hs.63489; -.
DR   PDB; 1FPR; X-ray; 2.50 A; A=243-526.
DR   PDB; 1GWZ; X-ray; 2.50 A; A=243-541.
DR   PDB; 1X6C; NMR; -; A=110-214.
DR   PDB; 2B3O; X-ray; 2.80 A; A=1-532.
DR   PDB; 2RMX; NMR; -; A=110-214.
DR   PDB; 2YU7; NMR; -; A=110-214.
DR   PDB; 3PS5; X-ray; 3.10 A; A=1-595.
DR   PDB; 4GRY; X-ray; 1.70 A; A=243-528.
DR   PDB; 4GRZ; X-ray; 1.37 A; A=243-528.
DR   PDB; 4GS0; X-ray; 1.80 A; A/B=243-528.
DR   PDB; 4HJP; X-ray; 1.40 A; A=243-528.
DR   PDB; 4HJQ; X-ray; 1.80 A; A/B=243-528.
DR   PDBsum; 1FPR; -.
DR   PDBsum; 1GWZ; -.
DR   PDBsum; 1X6C; -.
DR   PDBsum; 2B3O; -.
DR   PDBsum; 2RMX; -.
DR   PDBsum; 2YU7; -.
DR   PDBsum; 3PS5; -.
DR   PDBsum; 4GRY; -.
DR   PDBsum; 4GRZ; -.
DR   PDBsum; 4GS0; -.
DR   PDBsum; 4HJP; -.
DR   PDBsum; 4HJQ; -.
DR   ProteinModelPortal; P29350; -.
DR   SMR; P29350; -.
DR   BioGrid; 111742; 68.
DR   DIP; DIP-31002N; -.
DR   IntAct; P29350; 50.
DR   MINT; MINT-134053; -.
DR   STRING; 9606.ENSP00000391592; -.
DR   BindingDB; P29350; -.
DR   ChEMBL; CHEMBL3166; -.
DR   DEPOD; P29350; -.
DR   iPTMnet; P29350; -.
DR   PhosphoSitePlus; P29350; -.
DR   BioMuta; PTPN6; -.
DR   DMDM; 131469; -.
DR   OGP; P29350; -.
DR   EPD; P29350; -.
DR   MaxQB; P29350; -.
DR   PaxDb; P29350; -.
DR   PeptideAtlas; P29350; -.
DR   PRIDE; P29350; -.
DR   DNASU; 5777; -.
DR   Ensembl; ENST00000318974; ENSP00000326010; ENSG00000111679. [P29350-1]
DR   Ensembl; ENST00000399448; ENSP00000382376; ENSG00000111679. [P29350-3]
DR   Ensembl; ENST00000456013; ENSP00000391592; ENSG00000111679. [P29350-4]
DR   GeneID; 5777; -.
DR   KEGG; hsa:5777; -.
DR   UCSC; uc001qsb.3; human. [P29350-1]
DR   CTD; 5777; -.
DR   DisGeNET; 5777; -.
DR   GeneCards; PTPN6; -.
DR   HGNC; HGNC:9658; PTPN6.
DR   HPA; CAB004572; -.
DR   HPA; CAB072845; -.
DR   HPA; HPA001466; -.
DR   MIM; 176883; gene.
DR   neXtProt; NX_P29350; -.
DR   OpenTargets; ENSG00000111679; -.
DR   PharmGKB; PA34002; -.
DR   eggNOG; KOG0790; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   GeneTree; ENSGT00870000136380; -.
DR   HOGENOM; HOG000273907; -.
DR   HOVERGEN; HBG000223; -.
DR   InParanoid; P29350; -.
DR   KO; K05697; -.
DR   OMA; QAKGEPW; -.
DR   OrthoDB; EOG091G0VZ3; -.
DR   PhylomeDB; P29350; -.
DR   TreeFam; TF351632; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-388841; Costimulation by the CD28 family.
DR   Reactome; R-HSA-389948; PD-1 signaling.
DR   Reactome; R-HSA-391160; Signal regulatory protein (SIRP) family interactions.
DR   Reactome; R-HSA-432142; Platelet sensitization by LDL.
DR   Reactome; R-HSA-512988; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; R-HSA-5690714; CD22 mediated BCR regulation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912694; Regulation of IFNA signaling.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P29350; -.
DR   SIGNOR; P29350; -.
DR   ChiTaRS; PTPN6; human.
DR   EvolutionaryTrace; P29350; -.
DR   GeneWiki; PTPN6; -.
DR   GenomeRNAi; 5777; -.
DR   PMAP-CutDB; P29350; -.
DR   PRO; PR:P29350; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000111679; -.
DR   CleanEx; HS_PTPN6; -.
DR   ExpressionAtlas; P29350; baseline and differential.
DR   Genevisible; P29350; HS.
DR   GO; GO:0042105; C:alpha-beta T cell receptor complex; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IEA:Ensembl.
DR   GO; GO:0001784; F:phosphotyrosine binding; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; TAS:Reactome.
DR   GO; GO:0042169; F:SH2 domain binding; IEA:Ensembl.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:Ensembl.
DR   GO; GO:0005001; F:transmembrane receptor protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0033277; P:abortive mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IDA:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; IDA:UniProtKB.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0035855; P:megakaryocyte development; IEA:Ensembl.
DR   GO; GO:0042267; P:natural killer cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0050859; P:negative regulation of B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; NAS:UniProtKB.
DR   GO; GO:0002924; P:negative regulation of humoral immune response mediated by circulating immunoglobulin; IEA:Ensembl.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0070527; P:platelet aggregation; IEA:Ensembl.
DR   GO; GO:0030220; P:platelet formation; IEA:Ensembl.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:BHF-UCL.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0045577; P:regulation of B cell differentiation; IEA:Ensembl.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL.
DR   GO; GO:0051279; P:regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0060338; P:regulation of type I interferon-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   Gene3D; 3.30.505.10; -; 2.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR012152; Tyr_Pase_non-rcpt_typ-6/11.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF00017; SH2; 2.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PIRSF; PIRSF000929; Tyr-Ptase_nr_6; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SMART; SM00252; SH2; 2.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Hydrolase; Nucleus; Phosphoprotein; Protein phosphatase;
KW   Reference proteome; Repeat; SH2 domain.
FT   CHAIN         1    595       Tyrosine-protein phosphatase non-receptor
FT                                type 6.
FT                                /FTId=PRO_0000094758.
FT   DOMAIN        4    100       SH2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      110    213       SH2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      244    515       Tyrosine-protein phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION      453    459       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    453    453       Phosphocysteine intermediate.
FT   BINDING     419    419       Substrate. {ECO:0000250}.
FT   BINDING     500    500       Substrate. {ECO:0000250}.
FT   MOD_RES      10     10       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P81718}.
FT   MOD_RES      57     57       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P29351}.
FT   MOD_RES      64     64       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     377    377       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P29351}.
FT   MOD_RES     536    536       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P29351}.
FT   MOD_RES     564    564       Phosphotyrosine; by LYN.
FT                                {ECO:0000269|PubMed:10574931}.
FT   VAR_SEQ       1     39       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:1652101}.
FT                                /FTId=VSP_005129.
FT   VAR_SEQ       1      3       MVR -> MLSRG (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_007775.
FT   VAR_SEQ      40     44       SLSVR -> MLSRG (in isoform 3).
FT                                {ECO:0000303|PubMed:1652101}.
FT                                /FTId=VSP_005130.
FT   VAR_SEQ     559    595       HKEDVYENLHTKNKREEKVKKQRSADKEKSKGSLKRK ->
FT                                SLESSAGTVAASPVRRGGQRGLPVPGPPVLSPDLHQLPVLA
FT                                PLHPAADTRRMCMRTCTLRTRGRRK (in isoform 4).
FT                                {ECO:0000303|PubMed:10497187}.
FT                                /FTId=VSP_044447.
FT   CONFLICT      6      6       H -> L (in Ref. 5; AAA82880).
FT                                {ECO:0000305}.
FT   CONFLICT     86     86       L -> V (in Ref. 4; AAA36610 and 7;
FT                                AAD53317). {ECO:0000305}.
FT   CONFLICT    146    146       V -> E (in Ref. 5; AAA82880/AAA82879).
FT                                {ECO:0000305}.
FT   HELIX        11     21       {ECO:0000244|PDB:2B3O}.
FT   STRAND       26     31       {ECO:0000244|PDB:2B3O}.
FT   STRAND       33     45       {ECO:0000244|PDB:2B3O}.
FT   STRAND       48     55       {ECO:0000244|PDB:2B3O}.
FT   STRAND       57     59       {ECO:0000244|PDB:2B3O}.
FT   STRAND       61     63       {ECO:0000244|PDB:2B3O}.
FT   STRAND       68     70       {ECO:0000244|PDB:2B3O}.
FT   HELIX        72     80       {ECO:0000244|PDB:2B3O}.
FT   STRAND       89     91       {ECO:0000244|PDB:2B3O}.
FT   HELIX       105    107       {ECO:0000244|PDB:2B3O}.
FT   STRAND      111    114       {ECO:0000244|PDB:3PS5}.
FT   HELIX       117    127       {ECO:0000244|PDB:2B3O}.
FT   STRAND      132    137       {ECO:0000244|PDB:2B3O}.
FT   STRAND      139    141       {ECO:0000244|PDB:2B3O}.
FT   STRAND      145    154       {ECO:0000244|PDB:2B3O}.
FT   STRAND      155    157       {ECO:0000244|PDB:2RMX}.
FT   STRAND      162    170       {ECO:0000244|PDB:2B3O}.
FT   HELIX       172    174       {ECO:0000244|PDB:3PS5}.
FT   STRAND      175    181       {ECO:0000244|PDB:2B3O}.
FT   STRAND      184    186       {ECO:0000244|PDB:2B3O}.
FT   HELIX       187    197       {ECO:0000244|PDB:2B3O}.
FT   STRAND      199    201       {ECO:0000244|PDB:2RMX}.
FT   STRAND      202    204       {ECO:0000244|PDB:2B3O}.
FT   STRAND      205    207       {ECO:0000244|PDB:2RMX}.
FT   HELIX       221    223       {ECO:0000244|PDB:2B3O}.
FT   STRAND      236    238       {ECO:0000244|PDB:3PS5}.
FT   HELIX       244    256       {ECO:0000244|PDB:4GRZ}.
FT   TURN        257    259       {ECO:0000244|PDB:4HJP}.
FT   HELIX       263    266       {ECO:0000244|PDB:4GRZ}.
FT   HELIX       268    273       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      275    278       {ECO:0000244|PDB:1GWZ}.
FT   TURN        283    285       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      286    288       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      290    292       {ECO:0000244|PDB:4GS0}.
FT   STRAND      294    296       {ECO:0000244|PDB:3PS5}.
FT   TURN        297    300       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      301    307       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      309    312       {ECO:0000244|PDB:1GWZ}.
FT   HELIX       314    316       {ECO:0000244|PDB:1FPR}.
FT   STRAND      321    324       {ECO:0000244|PDB:4GRZ}.
FT   HELIX       329    331       {ECO:0000244|PDB:4GRZ}.
FT   HELIX       332    341       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      346    349       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      353    355       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      356    358       {ECO:0000244|PDB:1FPR}.
FT   STRAND      371    374       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      377    386       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      388    399       {ECO:0000244|PDB:4GRZ}.
FT   HELIX       400    402       {ECO:0000244|PDB:2B3O}.
FT   STRAND      403    405       {ECO:0000244|PDB:1FPR}.
FT   STRAND      407    414       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      419    421       {ECO:0000244|PDB:2B3O}.
FT   STRAND      424    426       {ECO:0000244|PDB:4GRZ}.
FT   HELIX       427    442       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      443    445       {ECO:0000244|PDB:4HJQ}.
FT   STRAND      449    452       {ECO:0000244|PDB:4GRZ}.
FT   STRAND      454    457       {ECO:0000244|PDB:4GRZ}.
FT   HELIX       458    476       {ECO:0000244|PDB:4GRZ}.
FT   HELIX       484    492       {ECO:0000244|PDB:4GRZ}.
FT   HELIX       502    523       {ECO:0000244|PDB:4GRZ}.
SQ   SEQUENCE   595 AA;  67561 MW;  4D7736C21D3542D2 CRC64;
     MVRWFHRDLS GLDAETLLKG RGVHGSFLAR PSRKNQGDFS LSVRVGDQVT HIRIQNSGDF
     YDLYGGEKFA TLTELVEYYT QQQGVLQDRD GTIIHLKYPL NCSDPTSERW YHGHMSGGQA
     ETLLQAKGEP WTFLVRESLS QPGDFVLSVL SDQPKAGPGS PLRVTHIKVM CEGGRYTVGG
     LETFDSLTDL VEHFKKTGIE EASGAFVYLR QPYYATRVNA ADIENRVLEL NKKQESEDTA
     KAGFWEEFES LQKQEVKNLH QRLEGQRPEN KGKNRYKNIL PFDHSRVILQ GRDSNIPGSD
     YINANYIKNQ LLGPDENAKT YIASQGCLEA TVNDFWQMAW QENSRVIVMT TREVEKGRNK
     CVPYWPEVGM QRAYGPYSVT NCGEHDTTEY KLRTLQVSPL DNGDLIREIW HYQYLSWPDH
     GVPSEPGGVL SFLDQINQRQ ESLPHAGPII VHCSAGIGRT GTIIVIDMLM ENISTKGLDC
     DIDIQKTIQM VRAQRSGMVQ TEAQYKFIYV AIAQFIETTK KKLEVLQSQK GQESEYGNIT
     YPPAMKNAHA KASRTSSKHK EDVYENLHTK NKREEKVKKQ RSADKEKSKG SLKRK
//
